KR20130133212A - 입원 및 다른 환자에서 OprF/I 물질 및 이의 용도 - Google Patents

입원 및 다른 환자에서 OprF/I 물질 및 이의 용도 Download PDF

Info

Publication number
KR20130133212A
KR20130133212A KR1020137015420A KR20137015420A KR20130133212A KR 20130133212 A KR20130133212 A KR 20130133212A KR 1020137015420 A KR1020137015420 A KR 1020137015420A KR 20137015420 A KR20137015420 A KR 20137015420A KR 20130133212 A KR20130133212 A KR 20130133212A
Authority
KR
South Korea
Prior art keywords
oprf
seq
binding
ala
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137015420A
Other languages
English (en)
Korean (ko)
Inventor
크리스토프 클라데
로베르트 슐레글
케르스틴 베스트리슈니히
Original Assignee
인터셀 오스트리아 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인터셀 오스트리아 아게 filed Critical 인터셀 오스트리아 아게
Publication of KR20130133212A publication Critical patent/KR20130133212A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020137015420A 2010-12-23 2011-03-18 입원 및 다른 환자에서 OprF/I 물질 및 이의 용도 Ceased KR20130133212A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061426760P 2010-12-23 2010-12-23
US61/426,760 2010-12-23
PCT/EP2011/054127 WO2012084272A1 (en) 2010-12-23 2011-03-18 Oprf/i agents and their use in hospitalized and other patients

Publications (1)

Publication Number Publication Date
KR20130133212A true KR20130133212A (ko) 2013-12-06

Family

ID=44210049

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137015420A Ceased KR20130133212A (ko) 2010-12-23 2011-03-18 입원 및 다른 환자에서 OprF/I 물질 및 이의 용도

Country Status (11)

Country Link
US (1) US20130266575A1 (https=)
EP (1) EP2655402A1 (https=)
JP (2) JP5893640B2 (https=)
KR (1) KR20130133212A (https=)
CN (1) CN103270047A (https=)
AU (1) AU2011348396A1 (https=)
BR (1) BR112013016254A2 (https=)
CA (1) CA2822684A1 (https=)
MX (1) MX2013007146A (https=)
WO (1) WO2012084272A1 (https=)
ZA (1) ZA201304235B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111249455A (zh) 2012-11-30 2020-06-09 葛兰素史密丝克莱恩生物有限公司 假单胞菌抗原和抗原组合
CN103983793A (zh) * 2014-05-29 2014-08-13 上海理工大学 一种含丽春红的蛋白质芯片点样缓冲液及其制备方法
EA201790489A1 (ru) 2014-08-29 2017-08-31 Сорренто Терапьютикс, Инк. ТЕРАПЕВТИЧЕСКИЕ СРЕДСТВА НА ОСНОВЕ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ OprF И OprI
ES2846881T3 (es) 2015-05-01 2021-07-30 Inhibrx Inc Moléculas que se dirigen al sistema de secreción de tipo III
WO2016193402A1 (en) 2015-06-03 2016-12-08 Valneva Austria Gmbh Pseudomonas vaccine
CA2991634C (en) 2015-07-16 2026-03-17 Inhibrx Biosciences, Inc. Multivalent and multispecific dr5-binding fusion proteins
FR3099160B1 (fr) * 2019-07-23 2022-05-06 Univ Grenoble Alpes Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
CN117222740A (zh) * 2022-06-07 2023-12-12 南方科技大学 编码PcrV和/或OprF-I蛋白的mRNA疫苗
CN116251178A (zh) * 2023-03-28 2023-06-13 吉林农业大学 一种铜绿假单胞菌疫苗及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494672A (en) * 1989-04-28 1996-02-27 S.P.I. Synthetic Peptides Incorporated Pseudomonas peptide composition and method
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
ATE190657T1 (de) * 1994-12-16 2000-04-15 Chiron Behring Gmbh & Co Immunogenes hybridprotein oprf-oprl erhältlich aus membranproteinen von pseudomonas aeruginosa
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
JP2005501889A (ja) * 2001-09-03 2005-01-20 アンビクス パテンツ−ライセンシーズ アーゲー マクロライド系抗生物質を用いる緑膿菌感染症の治療法
AU2002340683C1 (en) * 2001-11-13 2009-11-12 Id Biomedical Corporation Of Quebec Polypeptides of pseudomonas aeruginosa
ES2332590T3 (es) * 2003-01-15 2010-02-09 International Institute Of Cancer Immunology, Inc. Dimero peptidico.
EP1623229A2 (en) 2003-05-15 2006-02-08 Cytos Biotechnology AG Selection of b cells with specificity of interest: method of preparation and use
GB0410958D0 (en) * 2004-05-15 2004-06-16 Haptogen Ltd Methods for reducing biofilm formation in infectious bacteria
EP1861110B1 (en) * 2004-12-17 2014-03-26 Venus Remedies Limited Antibiotic combinations for providing total solution to the treatment of infections
EP1921142A1 (en) 2006-11-07 2008-05-14 Cytos Biotechnology AG Selection of human monoclonal antibodies by eukaryotic cell display
CN111249455A (zh) * 2012-11-30 2020-06-09 葛兰素史密丝克莱恩生物有限公司 假单胞菌抗原和抗原组合

Also Published As

Publication number Publication date
JP2014504297A (ja) 2014-02-20
CA2822684A1 (en) 2012-06-28
JP5893640B2 (ja) 2016-03-23
AU2011348396A1 (en) 2013-07-04
WO2012084272A1 (en) 2012-06-28
ZA201304235B (en) 2014-09-25
BR112013016254A2 (pt) 2017-07-11
US20130266575A1 (en) 2013-10-10
JP2016147867A (ja) 2016-08-18
CN103270047A (zh) 2013-08-28
MX2013007146A (es) 2013-11-01
AU2011348396A2 (en) 2013-07-11
EP2655402A1 (en) 2013-10-30

Similar Documents

Publication Publication Date Title
KR20130133212A (ko) 입원 및 다른 환자에서 OprF/I 물질 및 이의 용도
CN111690059B (zh) 一种抗SARS-CoV-2的单克隆抗体1D7
JP6048845B2 (ja) ジフテリア毒素の無毒性突然変異体ｃｒｍ１９７又はその断片を含む融合タンパク質
CN112521494B (zh) 一种抗SARS-CoV-2的单克隆抗体2B11
CN111732654B (zh) 一种抗SARS-CoV-2的单克隆抗体1E10
EP3038633B1 (en) Stable polypeptides binding to human complement c5
EP3805255A1 (en) Acinetobacter baumannii immunogenic protein and composition and application thereof
US20160362480A1 (en) Novel oprf/i fusion proteins, their preparation and use
CN105542003B (zh) 一种针对rsv粘附g蛋白表面抗原的全人源单克隆抗体
HK1188799A (en) Oprf/i agents and their use in hospitalized and other patients
CN113817051B (zh) 一种抗SARS-CoV-2的单克隆抗体1B6
EP3554639A1 (en) Novel recombinant protein uk 114 in stable polymer form for use in the treatment, diagnosis and prevention of malignant solid and systemic tumours
HK40050539B (en) Stable polypeptides binding to human complement c5
CN113817050A (zh) 一种抗SARS-CoV-2的单克隆抗体1H8
HK40050539A (en) Stable polypeptides binding to human complement c5
Sudarkina et al. Production and characterization of the B chains of mistletoe toxic lectins
KR20200082345A (ko) 암배항원을 표적화하는 재조합 면역독소 및 이를 포함하는 암 예방 또는 치료용 약학 조성물
BR122023020080B1 (pt) Polipeptídeos e compostos de ligação a c5 do complemento humano
HK1225656B (en) Stable polypeptides binding to human complement c5

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130614

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160308

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170523

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170725

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170523

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I